1
Return

Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate-to-Severe Atopic Dermatitis

delete2026-08-03
delete0
PRE
AI
M
Madeline Kim
E
Ester Del Duca
J
Joel Corrêa da Rosa
J
Juliana Pulsinelli
Y
Yeriel Estrada
D
Dan Xu
G
Gary Chan
A
Allshine Chen
E
Erman Güler
K
Karen Page
E
Emma Guttman‐Yassky *
DOI：10.1111/all.70467delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Atopic dermatitis (AD) is characterized by microbial dysbiosis, notably an overabundance of Staphylococcus species. This study aimed to evaluate the effects of abrocitinib, a Janus kinase 1-selective inhibitor, on the skin microbiome and clinical outcomes in patients with moderate-to-severe AD.
Keywords:
abrocitinib
atopic dermatitis
inflammation
JAK
JAK 1
microbiome
Staphylococcus aureus

Journal

A
Allergy
IF:
12
Papers:
9.3K
Citations:
2.6W

Organization

P
pfizer inc.
Scholars:
319
Papers: 95
Citations: 0
I
icahn school of medicine at mount sinai
Scholars:
3.1K
Papers: 1.1K
Citations: 0
Cited Papers

Cited Papers

Citing Papers

Citing Papers